BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
183 hedge funds and large institutions have $456M invested in bluebird bio in 2022 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 64 increasing their positions, 46 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
9% more capital invested
Capital invested by funds: $419M → $456M (+$37.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 4.25% → 4.1% (-0.16%)
Holders
183
Holding in Top 10
1
Calls
$8.46M
Puts
$4.89M
Top Buyers
| 1 | +$8.36M | |
| 2 | +$5.74M | |
| 3 | +$5M | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.35M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.33M |
Top Sellers
| 1 | -$11.8M | |
| 2 | -$8.49M | |
| 3 | -$6.4M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$4.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.82M |